Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Chiesi Farmaceutici S.p.A., Via Palermo, 26/A, 43122, Parma, Italy
Kengrexal 50 mg powder for concentrate for solution for injection/infusion.
| Pharmaceutical Form |
|---|
|
Powder for concentrate for solution for injection/infusion. White to off-white lyophilised powder. |
Each vial contains cangrelor tetrasodium corresponding to 50 mg cangrelor. After reconstitution 1 mL of concentrate contains 10 mg cangrelor. After dilution 1 mL of solution contains 200 micrograms cangrelor.
Excipient with known effect: Each vial contains 52.2 mg sorbitol.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cangrelor |
Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation in vitro and ex vivo. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signalling and platelet activation. |
| List of Excipients |
|---|
|
Mannitol |
Powder in 10 mL glass vials (Type 1) closed with a Flurotec coated butyl rubber stopper and sealed with crimped aluminium seal.
Kengrexal is available in packs of 10 vials.
Chiesi Farmaceutici S.p.A., Via Palermo, 26/A, 43122, Parma, Italy
EU/1/15/994/001
Date of first authorisation: 23 March 2015
| Drug | Countries | |
|---|---|---|
| KENGREXAL | Austria, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
